義大醫院 代理研究副院長

學術論文著作

1. 1.Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. Am J Gastroenterol. 2019 [Epub ahead of print]

2. 2.Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19 (10):1109-1120.

3. 3.Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH; REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019; 13(5):587-598.

4. Kao FC, Hsu YC, Liu PH, Tu YK, Jou IM. High 2-year mortality and recurrent infection rates after surgical treatment for primary septic arthritis of the hip in adult patients: An observational study. Medicine (Baltimore). 2019; 98(32):e16765.

5. Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients with Chronic Hepatitis B or C Infection. Hepatol Commun. 2019 8;3(4):493-503.

6. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389-398.

7. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med. 2019 [Epub ahead of print]

8. Jeng WJ, Hsu YC, Su TH, Chen CH. Deliberations more than a cut-off HBsAg value for Nuc cessation. 2019 [Epub ahead of print]

9. Lee TL, Kao FC, Hsu YC, Lo YY, Tu YK. Perioperative acute myocardial infarction rate in chronic renal disease patients undergoing orthopedic surgery: Is there any difference between dialyzed and nondialyzed patients? PLoS One. 2019;14(1):e0210554.

10. Hsu YC, Yip TC, Wong GL, Wu CY. Reply to: Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues. J Hepatol. 2019; 70 (4):796-797

11. Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, Tseng CH, Tai CM, Wu CY, Lin JT, Tanaka Y, Chang CY. Combining hepatitis B core‐related and surface antigens at end of nucleos(t)ide analogue treatment to predict off‐therapy relapse risk. Aliment Pharmacol Ther. 2019;49(1):107-115.

12. Hsu YC, Tseng CH, Kao JH. Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done. Clin Gastroenterol Hepatol. 2019;17(5):1000-1001.

13. Wei MT, Le AK, Chang MS, Hsu H (listed as Holden Hsu), Nguyen P, Zhang JQ, Wong C, Wong C, Cheung R, Nguyen MH. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. J Med Virol. 2019; 91(7):1288-1294.

14. Lai ZL, Tseng CH, Ho HJ, Cheung CKY, Lin JY, Chen YJ, Cheng FC, Hsu YC, Lin JT, El-Omar EM, Wu CY. Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. Sci Rep. 2018; 8(1):15625

15. Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, Cho SH, Lin JT, Yu ML, Nguyen MH, Tanaka Y. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018; 48(10):1128-1137.

16. Tseng CH, Chang CY, Mo LR, Lin JT, Tai CM, Perng DS, Lin CW, Hsu YC*. Acoustic Radiation Force Impulse Elastography with APRI and FIB-4 to Identify Significant Liver Fibrosis in Chronic Hepatitis B Patients. Ann Hepatol. 2018; 17(5):789-794.

17. Kao FC, Hsu YC, Wang CB, Tu YK, Liu PH. Short-term and long-term revision rates after lumbar spine discectomy versus laminectomy: a population-based cohort study. BMJ Open. 2018; 8(7):e021028.

18. Zou B, Yeo YH, Jeong D, Sheen E, Park H, Nguyen P, Hsu YC, Garcia G, Nguyen MH. Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. Sci Rep. 2018; 8(1):9969.

19. Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Efficacies of Genotypic Resistance-guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. 2018 Oct ;155(4):1109-1119

20. Kao FC, Hsu YC, Lai PY, Wang CB, Tu YK, Chen WK. One-year mortality and Periprosthetic infection rates after Total knee Arthroplasty in Cancer patients: a population-based cohort study. BMC Cancer. 2018; 18(1):628.

21. Yeh HF, Hsu YC, Clinciu DL, Tung HH, Yen YC, Kuo HC. Depression and young age impact on hip fracture subsequent to stroke: A population-based cohort study. Int J Nurs Pract. 2018 Oct ;24(5):e12665

22. Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL*, Wu CY*. Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B. J Hepatol. 2018 Oct; 69(2):278-285

23. Kao FC, Hsu YC, Liu PH, Yeh LR, Wang JT, Tu YK*. Osteoporotic sacral insufficiency fracture: An easily neglected disease in elderly patients. Medicine. 2017 Dec;96(51):e9100.

24. Wei YF, Chen JY, Lee HS, Wu JT, Hsu CK, Hsu YC*. Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ Open. 2018 Jan 24;8(1):e019661.

25. Chen CH, Hsu YC, Lu SN, Hung CH, Wang JH, Lee CM, Hu TH*. The incidence predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat.. 2018 May ;25(51):590-297

26. Tseng CH, Hsu YC (co-first), Chang CY, Tseng TC, Wu MS, Lin JT, Kao JH*. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. J Formos Med Assoc. 2018 Oct; 117(10):915-921.

27. Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC.* Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol. 2017; Dec 8;17(1):154.

28. Hsu YC, Ho HJ, Lee TY, Huang YT, Wu MS, Lin JT, Wu CY*, El-Serag HB*. Temporal Trend and Risk Determinants of Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients on Entecavir or Tenofovir. J Viral Hepat. 2018 May;25(5):543-551

29. Kao FC, Hsu YC,* Wu CH, Wang CB, Tu YK, Liu PH. Use of corticosteroids is not associated with repeated vertebroplasty or kyphoplasty within one year after the surgery in patient older than 50 years. Acta Orthop Traumatol Turc. 2017 Dec;51(6):459-465.

30. Surveillance group; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018 May; 117(5):381-403

31. Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol. 2017;11(11):999-1008

32. Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, Wu CY. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intra-hepatic Cholangioarcinoma in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2018 Jun;16(6):947-954

33. Lin IC, Lee CT, Hsu YC, Tseng CM. An unusual cause of upper gastrointestinal bleeding. Dig Liver Dis. 2018 Jan;50(1):92.

34. Tseng CM, Huang SP, Liao WC, Chiang CJ, Yang YW, Chang CY, Hsu YC* (co-corresponding), Chen HC*, Chiang HS, Lin JT. Incidence and mortality of pancreatic cancer on a rapid rise in Taiwan, 1999~2012. Cancer Epidemiology 2017 Aug;49:75-84

35. Kao FC, Hsu YC* (corresponding), Lin CJ, Lo YY, Tu YK. Corticosteroid Is Associated with Both Hip Fracture and Fracture-Unrelated Arthropathy. PLoS One. 2017;12(1):e0169468.

36. Hsu YC, Mo LR, Chang CY, Wu MS, Yang TH, Kao JH, Chen CC, Tseng CH, Tai CM, Lin CW, Wu CY, Lin JT. Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy. J Gastroenterol Hepatol. 2017;32(8):1512-1519

37. Chen CC, Hsu YC, Lee CT, Hsu CC, Tai CM, Wang WL, Tseng CH, Hsu CT, Lin JT, Chang CY. Central Obesity and H. pylori Infection Influence Risk of Barrett's Esophagus in an Asian Population. PLoS One. 2016;11(12):e0167815

38. Kao FC, Hsu YC* (corresponding), Chen WH, Lin JN, Lo YY, Tu YK. Prosthetic Joint Infection Following Invasive Dental Procedures and Antibiotic Prophylaxis in Patients with Hip or Knee Arthroplasty. Infect Control Hosp Epidemiol 2017; 38(2):154-161.

39. Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016; 388 (10058): 2355-2365.

40. Tseng CM, Liao WC, Chang CY, Lee CT, Tseng CH, Hsu YC* (corresponding), Lin JT. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan. Pancreatology 2017 Jan;17(1):76-82

41. Kao FC, Hsu YC* (corresponding), Yen CY, Lin CF, Wu CH, Tu YK. Revision and Survival Rates After Total Knee Arthroplasty in Individuals Aged 70 and Older. J Am Geriatr Soc 2016; 64 (11):e225-e227

42. Tseng CM, Chen TB, Hsu YC* (corresponding), Chang CY, Lin JT, Mo LR. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol. 2016; 12(4):421-429

43. Hsu YC*, Mo RY, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fan YJ, Hung HW, Wu CY*, Lin JT. Serum Levels of Hepatitis B Surface Antigen at Cessation of Entecavir Treatment Stratify Relapse Risk in End-of-therapy Hepatitis B E Antigen-negative Patients. Clin Gastroenterol Hepatol. 2016; 14(10):1490-1498.e3

44. Lo GH, Lin CW, Hsu YC. A controlled trial of early versus delayed feeding following ligation in the control of acute esophageal variceal bleeding. J Chin Med Assoc. 2015 Nov;78(11):642-7

45. Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. 2016; 65(11):1784–1792

國際醫學會研究發表 (僅列五年內第一作者)

2017: Hsu YC, Mo LR, Chang CY, Wu MS, Lin JT, Kao JH.
Quantification of serum hepatitis B core antibody to predict and monitor off-therapy response after cessation of nucleos(t)ide analogue treatment in chronic hepatitis B patients. Poster (PP1144) at the 26th conference of the Asian Pacific Association for the Study of the Liver (Shanghai, China). Hepatol Int (2017) 11 (Suppl 1):S734

2016: Hsu YC, Ho HJ, El-Serag HB, Lin JT, Wu CY.
Risk of Hepatocellular Carcinoma Decreases over Time in Chronic Hepatitis B Patients on Antiviral Therapy with Entecavir or Tenofovir. Oral presentation (OP103) at the 67 annual meeting of American Association for the Study of Liver Diseases (the Liver Meeting® 2016), Boston, USA.

2016: Hsu YC, Chang CY, Wu MS, Kao JH, Yang TH, Lin JT.
Risk of and Predictors for Clinical Events Following Virological Relapse in Chronic Hepatitis B Patients after Cessation of Nucleos(t)ide Analogue Therapy. Oral presentation (OP206) at the United European Gastroenterology Week 2016, Vienna, Austria.

2016: Hsu YC, Lin JT, Ho SJ, Wu CY.
HCV Infection is associated with Higher Risks of Mortality and Liver Cancer as Compared with HBV. Oral presentation (Young Investigator Award) at the Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatitis C 2016. Kaohsiung, Taiwan; June 12, 2016

2015: Hsu YC, Wu CY, Chang CY, Wu MS, Kao JH, Yang TH, Hung HW, Lin JT.
End-of-therapy Serum Gradient of Hepatitis B Surface Antigen Predicts Off-therapy Durability after Discontinuation of Nucleos(t)ide Analogues. Poster (Presidential Poster of Distinction) at the 66 annual meeting of American Association for the Study of Liver Diseases (the Liver Meeting®) 2015, San Francisco, USA

2014: Hsu YC, Lin JT, Ho JH, Chang CY, Wu CY.
Antiviral treatment and risk of end-stage renal disease in patients with hepatitis C virus infection. Oral presentation at the United European Gastroenterology Week 2014 (OP045, UEGW 2014), Vienna, Austria

2014: Hsu YC, Lin JT, Ho JH, Chang CY, Wu CY.
Antiviral treatment and risk of end-stage renal disease in patients with hepatitis C virus infection: a nationwide total population study. Oral presentation (Young Investigator Award) at the International Digestive Disease Forum (IDDF) 2014, Hong Kong

2013: Hsu YC, Wu CY, Chang CY, Mo LR, Lin JT.
Determinants of hepatocellular carcinoma in chronic hepatitis B patients with cirrhosis under continuous nucleos(t)ide analogues. Oral presentation (Oral Free Paper Prize) at the 21th United European Gastroenterology Week (OP234, UEGW 2013), Berlin, Germany. United European Gastroenterology Journal 2013; 1 (1S), A71

2012: Hsu YC, Lin JT, Ho HJ, Wu MS, Wu CY.
Postoperative antiviral therapy with pegylated interferon plus ribavirin associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Oral presentation at the 63 annual meeting of American Association for the Study of Liver Diseases (the Liver Meeting®) 2012 (Boston, USA). Hepatology 2012; 56 (4), supplement 1, 276A.

2012: Hsu YC, Wu CY, Chen ZT, Huang YT, Lin JT.
Remission of Diabetes Mellitus and Reduction of Diabetic Morbidity After Antiviral Treatment for Chronic Viral Hepatitis C. Oral presentation (Oral Free Paper Prize) at the 20th United European Gastroenterology Week (UEGW 2012), Amsterdam, Netherland. Gut 2012; 61(Suppl 3), A56

2012: Hsu YC, Wu CY, Chang CY, Tseng CH, Mo LR, Lin JT.
Role of pretreatment viral load in predicting mortality in chronic hepatitis B patients receiving antivirals for severe acute exacerbation. Oral presentation (Young Investigator Award) at the 3rd International Forum at the 98th General Meeting of Japanese Society of Gastroenterology (Tokyo, Japan; April 21, 2012)

2012: Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY.
Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. Poster at the 22nd conference of the Asian Pacific Association for the Study of the Liver 2012 (Taipei, Taiwan). Hepatology International 2012; 6(1): 294

2012: Hsu YC, Wu CY, Chang CY, Mo LR, Lin JT.
Predictive factors for mortality in patients with severe acute exacerbation of chronic hepatitis B. Poster at the 22nd conference of the Asian Pacific Association for the Study of the Liver 2012 (Taipei, Taiwan). Hepatology International 2012; 6(1): 133

2012: Hsu YC, Lin HH, Mo LR, Chang CY, Perng DS, Lo GH, Lin JT.
Early Experience with Tenofovir for Chronic Hepatitis B in an Asian Country: real-world data from Taiwan. Poster at the 22nd conference of the Asian Pacific Association for the Study of the Liver 2012 (Taipei, Taiwan). Hepatology International 2012; 6(1):107

學術榮譽獲獎 (僅列五年內個人獎項)

2016: Annual Research Award of Best Quality (1st runner-up) of E-Da Hospital (義大醫院年度論文最高品質獎第二名)